Andreas Möller, Professor, Director, JC STEM Lab of Personalized Cancer Medicine, Prince of Wales Hospital, Chinese University of Hong Kong
Andrew Godwin, Professor and Division Director, Deputy Director, KU Cancer Center, University of Kansas Medical Center
Mei He, Associate Professor, University of Florida -- Conference Chairperson
Noah Malmstadt, Professor, Mork Family Dept. of Chemical Engineering & Materials Science, University of Southern California
SelectBIOは、2025年10月6日 - 7日に、ホテル日航成田(成田国際空港そば)にて Extracellular Vesicles/Exosomes Asia 2025 を開催いたします。
会議は、次の2つのトラックで構成されます。
Lab-on-a-Chip, Microfluidics, Organoids and Organ-on-a-Chip Asia 2025
Extracellular Vesicles/Exosomes Asia 2025
出席者と出展者は、両方のトラックにフルアクセスし、最大限の科学的交流とネットワーキングを行うことができます。
SelectBIOによる Extracellular Vesicles/Exosomes Asia 2025 は、フロリダ大学の Mei He 教授が議長を務め、アジアにおける学術関係者、業界/企業関係者が一堂に会します。この会議の講演者は、EV研究ツール開発におけるインフラとイノベーションを提供する学術機関、企業、技術/ツール/計測機器企業です。
アジアにおける研究・診断・治療の観点から、細胞外小胞(EV)/エクソソームへの関心が高いことを踏まえ、この会議では、この分野のさまざまな関係者が一堂に会し、2日間にわたって集中的な科学プレゼンテーション、製品デモンストレーション、学生やポスドクによるポスター発表などを通じ、研究の説明と普及を図ります。
会議に参加しながら、ポスターで研究を発表することもできます。審査用にアブストラクトの提出が必須です。
ポスター発表の提出期限:2025年9月15日
Biomarker Content of Extracellular Vesicles and Role for Diagnostics
細胞外小胞(EV)におけるバイオマーカーコンテンツと診断の役割
Disease Areas where EV-based Diagnostics Being Developed
開発中のEVベース診断の疾患領域
Extracellular Vesicles (EVs): Therapeutic and Drug Delivery Potential
細胞外小胞(EV):治療とドラッグデリバリーの可能性
Single Extracellular Vesicle (EV) Analysis by Flow Cytometry
フローサイトメトリーによる単一の細胞外小胞(EV)分析
Technologies for Engineering EVs for Therapeutics, Drug Delivery
治療・ドラッグデリバリー向けEVのエンジニアリング技術
Technologies for the Isolation, Characterization and Study of Extracellular Vesicles (EVs)-Exosomes
細胞外小胞(EV)/エクソソームの単離、特性評価、研究の技術
詳細については、株式会社グローバルインフォメーションまでお問い合わせ下さい。
Andreas Möller, Professor, Director, JC STEM Lab of Personalized Cancer Medicine, Prince of Wales Hospital, Chinese University of Hong Kong
Andreas Möller Biographical Sketch
Professor Andreas Möller is a trained biochemist and cancer biologist, with >20 years’ experience in cancer research. He is Professor in the Faculty of Medicine at the Chinese University of Hong Kong, supported by the prestigious Global STEM Professor fellowship. In addition, he is the Director of the Jockey Club Laboratory of Precision Cancer Medicine at the Li Ka Shing Institute of Health Sciences. Previously, between 2012 and 2023, he led the Tumour Microenvironment Laboratory at the QIMRB Medical Research Institute, Brisbane, Australia. Professor Möller has a strong background in cancer cell biology, extracellular vesicle (EV) biology, hypoxia research, cancer metastasis and cancer immunology. He is Member of the Board of Directors of the International Society of Extracellular Vesicles since 2022, and since 2024 elected Executive Chair for Meetings and Programs as well as one of the founders and Executive Board Member of the Asia Pacific Societies of Extracellular Vesicles.
Andrew Godwin, Professor and Division Director, Genomic Diagnostics, Founding Director, Kansas Institute for Precision Medicine, Deputy Director, KU Cancer Center, University of Kansas Medical Center
Andrew Godwin Biographical Sketch
Andrew K. Godwin, PhD is the Chancellors Distinguished Chair in Biomedical Sciences endowed Professor and the Director of Molecular Oncology in the Department of Pathology at the University of Kansas Medical Center (KUMC). He is a leader in the field of translational research and precision medicine. A native of Lawrence, Kansas, Dr. Godwin graduated with highest distinction from the University of Kansas (KU) with a bachelor’s degree in Cellular Biology. He obtained his PhD in Molecular Biology from the University of Pennsylvania while carrying out his thesis research at Fox Chase Cancer Center (FCCC) in Philadelphia. While at FCCC he had the pleasure of learning from “giants” in their respective fields of cancer-focused science. He was appointed leader of the FCCC’s Cancer Center Support Grant Ovarian Cancer Program in 2008 and served as co-leader of the Women's Cancer Program from 2009 to 2010. He was the founding director of both the Clinical Molecular Genetics/Pathology Laboratory and the Biosample Repository at FCCC since their inception in 1995 and 1999 respectively, and until leaving FCCC.
Dr. Godwin was recruited to KUMC as the director of Molecular Oncology and as the Associate Director for Translational Research within the KU Cancer Center in October 2010 after 26 productive years at FCCC. His engaged participation in the cancer center led to being appointed the Deputy Director in 2013 and his unwavering efforts helped to gain NCI designation in 2012/2017 and comprehensive designation in 2022. He founded the Clinical Molecular Oncology Laboratory, a CLIA-certified, CAP-accredited molecular diagnostics laboratory in 2012. He was appointed the Division Director for Genomic Diagnostic for the KU Health System in 2020. He also founded the Center for Genetics Services and Health Equity, to address health disparities in medical underserved populations regionally and nationally.
Dr. Godwin holds secondary appointments as a Professor in the Department of Internal Medicine, and the Department of Microbiology, Molecular Genetics, and Immunology. He also leads the ovarian cancer research-working group, is a member of the Investigator Initiated Trial Steering Committee, serves as the founding Scientific Director for the Biomarker Discovery Laboratory, the Director of the KU Cancer Center’s Biospecimen Shared Resource, and the KU Medical Center’s Biospecimen Repository Core Facility. He was named the Vice Chair for the Breast Translational Medicine subcommittee of the Southwest Oncology Group in 2018 and was appointed to the National Cancer Institute’s NCTN Core Correlative Sciences Committee in 2021.
Dr. Godwin heads KU’s institutional efforts in precision medicine. In 2016 he founded the Kansas Institute for Precision Medicine which is currently supported by a Phase 2 Centers of Biomedical Research Excellence (P20 GM130423) grant from the NIGMS. He is also a co-founder of a startup company, Sinochips Diagnostics, a private reference laboratory that provides pharmacogenomic testing to provide a road map for which drugs will be most effective for each individual patient.
He was named a Kansas Bioscience Authority Eminent Scholar in 2010 and the University of Kansas School of Medicine Chancellor’s Distinguished Chair in Biomedical Sciences Endowed Professor in 2012. In 2014, Dr. Godwin received the KUMC School of Medicine’s Achievement Award for the mentoring of post-doctorate students. Of his awards, he is most proud of being acknowledged for his years of mentoring. He has mentored over 150 trainees, including high school students, undergraduates, graduate students, postdoctoral associates/fellows, medical students/fellows, visiting scientists, and junior faculty during his academic career. He was awarded the KU Medical Center’s Faculty Investigator Research Award in 2015, the University of Kansas Cancer Center Director’s William Jewell Team Science Award in 2017, the KUCC Director’s Basic Science Award and the Chancellor’s Club Award for Research in 2018, and the Dolph C. Simons, Sr. Higuchi Award in the Biomedical Sciences in 2020 – the state higher education system’s most prestigious recognition for scholarly excellence. Most recently, Godwin was presented with the 2021 KU School of Medicine Excellences in Mentoring (Faculty) award and the 2021 Cancer Center Director’s Award in Mentoring and was named the 2022 Lead Scholar in Biomedical Sciences by the Ewha Womans University in South Korea. Most recently he presented the 2024 Outstanding Mentorship in Pathology Award by the University School of Medicine and Department of Pathology and Laboratory Medicine in recognition of dedication to the mentorship and education of future pathologists.
Dr. Godwin is internationally recognized for his molecular biology/genetic studies of sarcoma (gastrointestinal stromal tumors and Ewing sarcoma), breast and ovarian cancer, and his efforts to help bridge the gap between basic and clinical science to improve patient care. As a result of his efforts, Dr. Godwin has been continuously since his first faculty appointment at the Fox Chase (in 1993) and has secured extramural funding totaling >$250M. He has published over 550 peer-reviewed manuscripts and scholarly review articles (h index = 143; >95,000 citations) and is the author of 4 patent applications.
Mei He, Associate Professor, University of Florida
Mei He Biographical Sketch
Dr. He is an associate professor from the Department of Pharmaceutics, College of Pharmacy at the University of Florida. She obtained her PhD degree from the University of Alberta and postdoc training from the University of California, Berkeley. Dr. He is the Editorial Board member of Pharmaceutics and AAPS Scientific Programming Committee Track Leader, as well as the Advisory Board Member of journal Lab on Chip (LOC). Her journal review efforts have been recognized as the Outstanding Reviewers in 2018, 2020, and 2021 from the LOC Royal Society of Chemistry. Dr. He Received NIH Maximizing Investigator’s Research Award for Early Stage Investigators in 2019, and she also received the LOC Emerging Investigator Award in 2019. Her multiple publications received the Most Download Articles of 2016 (LOC), the Featured Cover Story of 2018 (LOC), Technology Readers Choice Award of 2018 (SLAS), and Top 100 Read Articles of 2019 (Scientific Reports from Nature Publishing Group). Her recent publication is appeared in the journal of Nature Biomedical Engineering and highlighted as the Editorial Story. Dr. He research brings in novel technology platforms for differentiating, isolating, and intravesicular loading exosomes precisely, which presents a new way for developing precision medicine Dr. He’s innovation leads to 17 pending and issued patents and have been licensed by multiple companies and commercialized on the market. Particularly, she founded a few startup companies for advancing the innovative exosome research.
Noah Malmstadt, Professor, Mork Family Dept. of Chemical Engineering & Materials Science, University of Southern California
Noah Malmstadt Biographical Sketch
Noah Malmstadt is Professor at the University of Southern California. He received a BS in Chemical Engineering from Caltech and a PhD in Bioengineering from the University of Washington. Following postdoctoral work at UCLA, he joined the Mork Family Department of Chemical Engineering and Materials Science at USC in 2007. Malmstadt is the recipient of a 2012 Office of Naval Research Young Investigator award. His research focuses on microfluidic strategies to facilitate material fabrication and biophysical analysis. He has pioneered the integration of ionic liquids as solvents in droplet microreactors and the application of microfluidic systems to synthesizing biomimetic cell membranes. Microfluidic analytical techniques he has developed include methods for measuring the permeability of cell membranes to druglike molecules and techniques for measuring ionic currents through membrane proteins.
審査に通過すると、ポスター発表に必要な情報がすべて提供されます。
アジェンダのトピック
アブストラクトの内容については、発表者/著者が全責任を負うものとし、共著者全員がその内容を認識しているものとします。経歴、サマリー、アブストラクトは、Webサイトや会議資料で使用される可能性があることをご了承ください。
2025年10月6日
08:00
大空の間
Conference Registration, Materials Pick-Up, Coffee, Tea and Networking in the Exhibit Hall
会議の登録、資料の受け取り、展示ホールでのコーヒー・ティー・ネットワーキング
2025年10月6日
09:00
鶴の間
Chairperson's Opening Remarks
議長による開会の挨拶
Mei He, Associate Professor, University of Florida, United States of America
Chairperson's Welcome and Introduction to the Conference and Topics Addressed
議長による歓迎と会議の紹介、会議で取り上げられるトピック
2025年10月6日
09:15
大空の間
Keynote Presentation
基調講演
Andreas Möller, Professor, Director, JC STEM Lab of Personalized Cancer Medicine, Prince of Wales Hospital, Chinese University of Hong Kong
Translation of Extracellular Vesicles from Bench to Bedside
細胞外小胞(EV)における基礎研究から臨床(B2B)への応用
Extracellular vesicles (EVs) present a huge, yet largely untapped resource for disease diagnostics and therapeutics. While significant advancements have been made in bench-based investigations, these have largely not yet been successfully translated to clinical or commercial applications. In the context of cancer, the evaluation of EV cargo composition changes allowed us to develop highly sensitive, liquid biopsy diagnostic and prognostic biomarkers. In this presentation, the translational work, including the validation in retrospective patient cohorts and prospective trials will be discussed. Some of the technical and logistic challenges faced when transitioning bench methods to bedside applications, and their implementation into a hospital setting, will be highlighted.
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。>
詳細については、株式会社グローバルインフォメーションまでお問い合わせ下さい。
スペシャリスト:SelectBIOは、創薬とライフサイエンスの会議に特化しています。SelectBIOのスタッフの多くは、バイオサイエンスの資格を持ち、長年の経験を有しています。そのため、専門用語で対応し、ニーズを理解することができます。
優れたカスタマーサービス:SelectBIOの営業チームが、専門的なアドバイスやカスタマイズパッケージでサポートいたします。契約後からイベント開催前・イベント開催中も、カスタマーサービス部門が考慮すべき事項をすべてお知らせいたします。
SelectBIO is delighted to host Extracellular Vesicles/Exosomes Asia 2025 Conference at the:
Hotel Nikko Narita
500 Tokko Narita-shi
Chiba 286-0106
Japan
Telephone: +81-476-32-0032
The Hotel Nikko Narita is very easily accessible from international destinations via Tokyo Narita International Airport (Airport Code: NRT).
The hotel can be accessed easily from Narita International Airport via a complimentary bus, usually around 10-15 minutes to and from the airport, depending on terminal chosen.
Distance-wise airport to the hotel is approximately 3 kilometers (1.8 miles).
If you are arriving to Narita Terminal 1, the shuttle to the hotel stops at bus stop # 16.
If you are arriving to Narita Terminal 2, the shuttle to the hotel stops at bus stop # 33.
Guests can make hotel bookings as well as see the different room types on the hotel website.
The hotel website with details is at the link below.
For any hotel reservation-related issues, or if you need any help with hotel bookings, please contact us.
SelectBIO has NOT authorized ANY third party company to assist in hotel bookings or reservations for the conference. Please do NOT do business with any third party companies. If in doubt, please contact us immediately to clarify.
3D-Printing of Microfluidics
マイクロ流体力学の3Dプリンティング
2025年10月1日 19:30 - 21:30
鶴の間(ホテル日航成田)
Noah Malmstadt, Professor of Chemical Engineering and Materials Science, University of Southern California
3Dプリンティングは、複雑な流路構造を持つマイクロ流体デバイスを3Dで迅速に製造する方法として人気を集めています。
このショートコースの内容:
マイクロ流体ファブリケーションに適用される3Dプリンティング技術のメカニズム
マイクロ流体プリンティングにおける商業化が可能な最新のソリューション
3Dプリンテッドマイクロ流体システムにおけるアプリケーションと限界
新興技術と将来技術がマイクロ流体ファブリケーションツールとしての3Dプリンティングの可能性をどのように向上させるか?
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。